Xin Cheng

Title: **Inventor Xin Cheng: Pioneering Heterocyclic Compounds for Cancer Treatment**

Introduction

Xin Cheng is a notable inventor based in Zhejiang, China, who has made significant contributions to the field of pharmaceuticals. With one patent to his name, Cheng's research focuses on innovative compounds that can potentially revolutionize cancer treatment.

Latest Patents

His patent, titled *Heterocyclic Compound as CDK-HDAC Dual Pathway Inhibitor*, introduces novel compounds represented by a specific formula. This invention encompasses not only these heterocyclic compounds but also their pharmaceutically acceptable salts, hydrates, or solvates. Moreover, the patent details pharmaceutical compositions of these compounds and outlines methods for their preparation, alongside their therapeutic applications for treating various diseases, including cancers.

Career Highlights

Xin Cheng is currently affiliated with Hangzhou Innogate Pharma Co., Ltd., a company that specializes in the development of innovative pharmaceutical solutions. His role at the company reflects his dedication to advancing medical research and developing therapies that address critical health challenges.

Collaborations

Cheng has collaborated with esteemed colleagues in his field, including Hancheng Zhang and Xiangyang Ye. Their collective efforts highlight the importance of teamwork in driving innovation and advancing research in pharmaceuticals.

Conclusion

With his pioneering work in the development of heterocyclic compounds, Xin Cheng is poised to make a lasting impact in the fight against cancer. His contributions to the pharmaceutical industry not only demonstrate his expertise as an inventor but also underscore the potential for future innovations in medical treatments.